GoKawiilModerna Stock Drops 25% Despite Positive Melanoma Vaccine Data
Moderna's shares fell as much as 25% after partial trial results for its personalized melanoma vaccine, developed with Merck, leaked ahead of the official release. The full data showed the vaccine combined with Merck's Keytruda cut recurrence or death risk by 42% versus Keytruda alone, with 82% of patients cancer-free at two years compared to 70% on Keytruda alone.